2008-10-29 16:03:03 -

www.enzon.com - Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) announced today that it will report its financial results for the quarter ended September 30, 2008, on Wednesday, November 5, 2008 at approximately 8:00 am Eastern Time (ET). The release will be followed by a live conference call, which will begin at approximately 9:00 am Eastern Time (ET) on Wednesday, November 5, 2008.

Participating in the call from Enzon's executive management team will be Jeffrey H. Buchalter, Chairman and Chief Executive Officer, and Craig Tooman, Executive Vice President, Finance and Chief Financial Officer.

All interested parties may access the call by using the following information: -0- Domestic Dial-In Number: (866) 334-4934 International Dial-In Number: (416) 849-4293 Access Code: Enzon

The

call will also be available live audio webcast at www.investorcalendar.com. Listeners should go to the website at least fifteen minutes before this event to download and install any necessary audio software. For those unable to attend the live audio webcast, a replay will be available beginning approximately one hour after the event. Additionally, a telephonic rebroadcast will also be available following the call. The rebroadcast will begin on Wednesday, November 5, 2008 at approximately 12:00 pm Eastern Time (ET) and end on Wednesday, November 12, 2008 at approximately 12:00 pm Eastern Time (ET). It may be accessed using the following information: -0- Domestic Dial-In Number: (866) 245-6755 International Dial-In Number: (416) 915-1035 Access Code: 98757

About Enzon

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development, manufacturing, commercialization of important medicines for patients with cancer and other life-threatening conditions. Enzon has a portfolio of four marketed products, Oncaspar(R), DepoCyt(R), Abelcet(R) and Adagen(R). The Company's drug development programs utilize several cutting-edge approaches, including its industry-leading PEGylation technology platform used to create product candidates with benefits such as reduced dosing frequency and less toxicity. Enzon's PEGylation technology was used to develop two of its products, Oncaspar and Adagen, and has created a royalty revenue stream from licensing partnerships for other products developed using the technology. Enzon also engages in contract manufacturing for several pharmaceutical companies to broaden the Company's revenue base. Further information about Enzon and this press release can be found on the Company's web site at www.enzon.com.

Enzon Pharmaceuticals, Inc.
Craig Tooman, 908-541-8777
EVP, Finance and Chief Financial Officer